NCT07222800 2026-04-08
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
Clinical Trials
80 trialsNCT07377487 2026-03-30
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT05063565 2026-03-27
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07351071 2026-03-17
SECURE
Medtronic - MITG
Phase NA Recruiting
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03151564 2026-03-05
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT03214510 2026-03-05
Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04457297 2026-01-21
ALTAIR
National Cancer Center Hospital East
Phase 3 Completed
NCT05066139 2026-01-05
EPODIG-G
Centre Paul Strauss
Phase NA Recruiting
NCT02156739 2025-12-22
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05489237 2025-11-17
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
Phase 1 Recruiting
NCT06817161 2025-10-07
ESTANVO
Centre Francois Baclesse
Phase 3 Recruiting
NCT05612347 2025-09-23
COOP
Dartmouth-Hitchcock Medical Center
Phase NA Recruiting
NCT06929845 2025-09-15
Organoid Models of Hepatocellular Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT01047735 2025-07-11
TRIABETES
University of Pittsburgh
Phase NA Active not recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT03767517 2025-05-23
A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders
University of Alabama at Birmingham
Phase NA Completed
NCT01550510 2025-05-06
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University
Phase 1/2 Terminated
NCT01555489 2025-05-04
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Thomas Jefferson University
Phase 2 Terminated
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT05786482 2025-01-06
EMPOwer
University of Alberta
Phase NA Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT04084249 2024-07-09
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
University of Aarhus
Phase NA Active not recruiting
NCT03077685 2024-06-24
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NanOlogy, LLC
Phase 2 Completed
NCT05160168 2024-06-05
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
Phase 1/2 Terminated
NCT01832116 2024-05-03
MMOT
University Medical Center Groningen
Phase 1 Completed
NCT00838578 2024-04-26
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT06153394 2024-04-23
PRIORITY
Western University, Canada
Phase 3 Not yet recruiting
NCT06365866 2024-04-15
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
Taipei Veterans General Hospital, Taiwan
Phase NA Recruiting
NCT03464305 2024-03-19
ASPIRIN
University Hospital, Antwerp
Phase 3 Active not recruiting
NCT05442632 2024-03-13
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
Fudan University
Phase 2 Unknown
NCT03549494 2024-02-07
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Catalysis SL
Phase 2 Completed
NCT03559543 2024-02-07
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
Catalysis SL
Phase 2 Completed
NCT05200325 2023-12-04
Clinical Utility Evidence for TissueCypher®
Qure Healthcare, LLC
Phase NA Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05494060 2023-11-07
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05602935 2023-09-28
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
Phase 2 Active not recruiting
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT03717298 2023-03-28
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Catalysis SL
Phase 2 Completed
NCT05662813 2022-12-23
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
West China Hospital
Phase 2 Unknown
NCT05252078 2022-12-16
ALTER-E005
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT04080843 2022-07-13
ALTER-C-002
Zhejiang University
Phase 2 Completed
NCT04639115 2022-06-14
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
Celgene
Phase 1 Completed
NCT05228587 2022-03-04
LivInG
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Unknown